Skip to Content

Cannabics Pharmaceuticals Inc CNBX

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Cannabics Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing advanced HTS technology and personalized bioinformatics tools. The company's main focus is the development of therapies and biotechnological tools aimed at diverse ailments and human malignancies. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. Its advanced tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.

No. 3 Bethesda Metro Center, Suite 700
Bethesda, MD, 20814
T +1 877 424-2429
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Nov 30, 2021
Fiscal Year End Aug 31, 2022
Stock Type Distressed
Employees 10